Orthopaedic Surgery

Medicine & Life Sciences

1. Spine 100%
2. Scoliosis 93%
3. Osteosarcoma 85%
4. Pediatrics 60%
5. Bone and Bones 54%
6. Shoulder 44%
7. Arthroplasty 44%
8. Wounds and Injuries 42%
9. Orthopedics 39%
10. Therapeutics 38%
11. Pain 37%
12. Knee Replacement Arthroplasties 35%
13. Joints 33%
14. Surgeons 33%
15. Knee 32%
16. Child 32%
17. Tibial Fractures 31%
18. Hip 31%
19. Orthopedic Surgeons 28%
20. Guidelines 28%
21. Neoplasms 27%
22. Humerus 25%
23. Thigh 25%
24. Osteocytes 23%
25. Spondylolisthesis 23%
26. Systematic Reviews 22%
27. Reoperation 22%
28. Spinal Fusion 21%
29. Infections 21%
30. Clubfoot 21%
31. Sarcoma 19%
32. Length of Stay 19%
33. Foot 18%
34. Cerebral Palsy 18%
35. Lower Extremity 17%
36. Osteoarthritis 17%
37. Kyphosis 17%
38. Body Mass Index 17%
39. Slipped Capital Femoral Epiphyses 17%
40. Mesenchymal Stem Cells 17%
41. Osteoblasts 16%
42. Femur 16%
43. Antimicrobial Stewardship 16%
44. Thorax 16%
45. Nails 15%
46. Low Back Pain 15%
47. Population 15%
48. Connexin 43 14%
49. Operating Rooms 14%
50. Incidence 14%
51. Transplants 13%
52. Allografts 13%
53. Neoplasm Metastasis 13%
54. Pedicle Screws 13%
55. Osteotomy 13%
56. Growth 13%
57. Cell Line 13%
58. Infectious Arthritis 12%
59. Hip Fractures 12%
60. Intramedullary Fracture Fixation 12%
61. Anterior Cruciate Ligament Reconstruction 12%
62. Arthroscopy 12%
63. Anti-Bacterial Agents 12%
64. Tenocytes 12%
65. Equipment and Supplies 12%
66. Orthopedic Procedures 12%
67. Quality of Life 12%
68. Plantar Plate 11%
69. Confidence Intervals 11%
70. Elbow 11%
71. Arthrodesis 11%
72. Sacroiliac Joint 11%
73. Somatomedin Receptors 10%
74. Gait 10%
75. Obesity 10%
76. Chondrocytes 10%
77. Metatarsal Bones 10%
78. Costs and Cost Analysis 10%
79. Health Care Outcome Assessment 10%
80. Adenosine Triphosphate 10%
81. Operative Time 10%
82. Ewing's Sarcoma 10%
83. Biomechanical Phenomena 10%
84. Ankle Fractures 10%
85. Legg-Calve-Perthes Disease 10%
86. Upper Extremity 9%
87. Purinergic P2X7 Receptors 9%
88. Arthritis 9%
89. Femoral Nerve 9%
90. Morbidity 9%
91. Rehabilitation 9%
92. Matrix Metalloproteinase 13 9%
93. Gait Analysis 9%
94. Comorbidity 9%
95. Conservative Treatment 9%
96. Bone Morphogenetic Protein 2 9%
97. Metatarsophalangeal Joint 9%
98. Reduced Folate Carrier Protein 9%
99. Magnetic Resonance Imaging 9%